Inteliview
Log inSign up
US StocksPOSITIVE

Deutsche Bank Raises Humana Target 87% to $441 — Cigna Cut to Hold in Healthcare Sector Reset

Deutsche Bank upgraded Humana to Buy with an $441 target from $235 Hold (+87%), alongside upgrades on Centene and Elevance Health. Cigna was cut to Hold amid multi-year PBM transition uncertainty.

Justin Jeon··5 min read
Also available in Korean한국어로 보기 →
humana-cigna-deutsche-bank-upgrade-downgrade-2026
humana-cigna-deutsche-bank-upgrade-downgrade-2026
AIKey Summary
  • Deutsche Bank upgraded Humana to Buy with an $441 target (from $235), calling 2026 the earnings trough with a 2027 rebound expected
  • Centene and Elevance Health were also upgraded
  • Cigna was cut to Hold

Deutsche Bank overhauled its managed care coverage on May 20, upgrading Humana to Buy with an $441 target (from $235 Hold) while downgrading Cigna. Three healthcare insurers upgraded in a single call.


Deutsche Bank made sweeping changes to its managed care ratings on May 20. Humana (HUM), Centene (CNC), and Elevance Health (ELV) were all upgraded to Buy, while Cigna (CI) was cut to Hold. On the same day, other banks issued upgrades on Gilead (GILD), Rubrik (RBRK), and C.H. Robinson (CHRW).


Humana Target Raised 87% to $441 — From $235 Hold

Deutsche Bank upgraded Humana from Hold to Buy and raised its price target from $235 to $441. The rationale: 2026 is expected to be the earnings trough for Humana and a rebasing year, with the October Medicare Advantage star ratings being the critical variable for 2027 momentum. Deutsche simultaneously upgraded Centene (CNC) and Elevance Health (ELV) to Buy, signaling broad sector optimism.

2026 should be the earnings bottom for Humana and a rebasing year, depending on stars results in October.

Deutsche Bank Research

Cigna Cut to Hold — Multi-Year Business Transition Risk

Cigna (CI) was downgraded from Buy to Hold with a barely changed price target of $302 from $303. Deutsche Bank cited "multi-year uncertainty" as the company transitions part of its insurance portfolio and its pharmacy benefit manager (PBM) model. The bank sees Cigna as a longer-duration story rather than a near-term catalyst name.


Other Key Upgrades — Gilead, Rubrik, C.H. Robinson

  • Gilead (GILD): Maxim upgraded to Buy, $165 PT. Base business growth of 5-6% ahead of prior 4-5% estimate; HIV dominance, Yeztugo (PrEP), and Trodelvy (first-line breast cancer) justify a peer premium.
  • Rubrik (RBRK): Oppenheimer upgraded to Outperform, $85 PT. VAR channel checks confirm sharp recovery in backup and cyber-resilience demand.
  • C.H. Robinson (CHRW): Jefferies upgraded to Buy, $200 PT. HQ visit materially reinforced conviction in technology and productivity transformation.
  • Etsy (ETSY): Arete upgraded to Buy, $76 PT. GMV growth rates finally showing signs of improvement.

Key Downgrades — Newell Brands and Dominion

Morgan Stanley downgraded Newell Brands (NWL) to Underweight with a $3.50 target from $4, citing Iran-war-driven consumer sentiment weakness and cost pressures likely to push results below consensus in H2 2026 and FY27. Seaport Research cut Dominion (D) to Neutral following NextEra Energy's all-stock acquisition announcement, with the stock having reached the prior $67 target and a lengthy regulatory approval process seen as a headwind.

Loading...

Frequently Asked Questions

Why did Deutsche Bank upgrade Humana so aggressively?

Deutsche Bank sees 2026 as the earnings trough for Humana, with a potential rebound in 2027 depending on the October Medicare Advantage star ratings. The target was raised 87% from $235 to $441.

Why was Cigna downgraded to Hold?

Deutsche Bank cited "multi-year uncertainty" as Cigna transitions part of its insurance portfolio and PBM model. The bank views Cigna as a longer-duration story with no near-term catalyst.

What is the broader view on the managed care sector?

Deutsche Bank is bullish on the sector, upgrading Humana, Centene, and Elevance Health simultaneously. The thesis is that 2026 is the earnings bottom with a rebound expected in 2027.

What drove the Gilead upgrade?

Maxim upgraded Gilead to Buy with a $165 target, citing base business growth of 5-6% (above prior 4-5% estimate), HIV treatment dominance, and upside from Yeztugo and Trodelvy.

Why was Rubrik (RBRK) upgraded?

Oppenheimer lifted Rubrik to Outperform with an $85 target. VAR channel checks confirm a sharp recovery in backup and cyber-resilience demand.

Justin Jeon
Author

Justin Jeon

Topics
FREE MEMBERSHIP

Did you find this useful?

Sign up to bookmark articles, follow gurus, and manage your portfolio — all for free.

Guru trade alerts
Portfolio tracker
Article bookmarks

Related Articles

Wall Street's Defining Moments

See more
Browse defining moments

Insights

INTELIVIEW NEWSLETTER

Smart Money Briefing

Weekly summaries of Wall Street guru moves and crypto whale activity.